

Helus Pharma (Cybin) shares fall after Phase 2 anxiety drug results show symptom improvement, but pressure on the stock.
You can purchase shares of Helus Pharma (NASDAQ:HELP) through any online brokerage.
Other companies in Helus Pharma’s space includes: Eli Lilly and Co (NYSE:LLY), Johnson & Johnson (NYSE:JNJ), Merck & Co Inc (NYSE:MRK), Novartis AG (NYSE:NVS) and AstraZeneca PLC (NYSE:AZN).
Helus Pharma has a consensus price target of $46.20.
The stock price for Helus Pharma (NASDAQ: HELP) is $10.59 last updated November 16, 2026 at 6:07 AM EST.
There are no upcoming dividends for Helus Pharma.
Helus Pharma does not have any upcoming earnings scheduled.
There is no upcoming split for Helus Pharma.
Helus Pharma is in the Health Care sector and Pharmaceuticals industry. They are listed on the NASDAQ.
Helus Pharma Inc, the commercial operating name of Cybin Inc, is a clinical-stage pharmaceutical company focused on developing proprietary neuroactive compounds, referred to as NSAs, which are synthetic molecules designed to target serotonin...